See feature articles below:

About Broad Street Alerts:
Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
–Report on:(Nasdaq: VNCE )

Vince Holding Corp (NASDAQ:VNCE) Director Marc J. Leder purchased 195,663 shares of the business’s stock in a transaction on Thursday, April 21st. The stock was bought at an average cost of $5.50 per share, for a total transaction of $1,076,146.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Vince Holding Corp (NASDAQ:VNCE) opened at 6.76 on Wednesday. Vince Holding Corp has a 1-year low of $3.31 and a 1-year high of $18.95. The company has a 50 day moving average of $6.61 and a 200 day moving average of $5.26. The firm has a market capitalization of $248.63 million and a P/E ratio of 18.62.

Vince Holding Corp (NASDAQ:VNCE) last released its quarterly earnings results on Tuesday, March 29th. The company reported $0.01 EPS for the quarter. During the same quarter last year, the business earned $0.28 EPS. The firm had revenue of $81.80 million for the quarter. The firm’s quarterly revenue was down 13.6% compared to the same quarter last year. On average, equities research analysts anticipate that Vince Holding Corp will post $0.03 earnings per share for the current year.

Several analysts have issued reports on VNCE shares. B. Riley reaffirmed a “neutral” rating and set a $7.00 price target on shares of Vince Holding Corp in a research report on Sunday, March 13th. Piper Jaffray reaffirmed a “neutral” rating and set a $6.00 price target on shares of Vince Holding Corp in a research report on Tuesday, March 8th. Stifel Nicolaus reaffirmed a “hold” rating on shares of Vince Holding Corp in a research report on Monday, March 7th. Goldman Sachs upped their price target on shares of Vince Holding Corp from $5.00 to $5.50 and gave the stock a “neutral” rating in a research report on Friday, April 1st. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $8.00 price target on shares of Vince Holding Corp in a research report on Thursday, April 7th. One equities research analyst has rated the stock with a sell rating and eight have given a hold rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $6.07.

A hedge fund recently raised its stake in Vince Holding Corp stock. Chevy Chase Trust Holdings boosted its position in Vince Holding Corp (NASDAQ:VNCE) by 26.9% during the fourth quarter, Holdings Channel reports. The firm owned 457,224 shares of the company’s stock after buying an additional 96,839 shares during the period. Chevy Chase Trust Holdings owned about 1.24% of Vince Holding Corp worth $2,094,000 as of its most recent SEC filing.

Vince Holding Corp. (NASDAQ:VNCE) is a contemporary fashion brand known for modern style and everyday luxury essentials. The Company offers a range of women’s, men’s and children’s apparel, women’s and men’s footwear, and handbags.

Source: Watchlist
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.

See feature articles below:

 

About Broad Street Alerts:

Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

 

Article for NMI Holdings

 

NMI Holdings, Inc. (NASDAQ:NMIH) today reported results for the first quarter ended Mar. 31, 2016. In the first quarter, monthly premium new insurance written (NIW) was $2.5 billion, up 23% over $2.0 billion in the prior quarter and up 170% compared with the first quarter of 2015.

The company reported a net loss for the first quarter of $3.9 million, or $0.07 per share, which compares with a net loss of $4.8 million, or $0.08 per share, in the prior quarter and a net loss of $7.8 million, or $0.13 per share, in the first quarter of 2015. In the first quarter, total revenue was $22.2 million, which compares with $18.9 million in the prior quarter and $9.1 million in the first quarter of 2015.

Bradley Shuster, chairman and CEO of National MI, said, “National MI delivered another excellent quarter, achieving total NIW of $4.3 billion, up more than 150% over the first quarter of 2015. Importantly, in the first quarter we grew monthly product by 23% over the prior quarter. This was on top of the 28% sequential increase achieved in the fourth quarter of 2015. Primary insurance-in-force grew 25% to $18.6 billion, driving record levels of earned premiums. We continue to expect GAAP profitability in the second half of 2016 and thereafter to demonstrate the growing earnings leverage this business produces as we scale into our largely fixed expense base. In addition, we currently are negotiating reinsurance relationships that we believe will provide substantial capital credit while allowing for continued growth in net premiums and the generation of internal capital. We expect that reinsurance will become a permanent part of our capital structure and will allow us to defer indefinitely an equity capital raise.”

— Total NIW of $4.3 billion in the first quarter compares with total NIW
of $4.5 billion in the prior quarter and total NIW of $1.7 billion in
the first quarter of 2015.
— Monthly premium NIW was $2.5 billion, an increase of 23% over $2.0
billion in the prior quarter and an increase of 170% over the first
quarter of 2015. Single premium NIW of $1.8 billion was down 30% from
the prior quarter and up 128% compared with the same quarter a year ago.
— Premiums earned for the quarter were $19.8 million, up from $16.9
million in the prior quarter and $6.9 million in the same quarter a year
ago.
— Investment income in the first quarter was $3.2 million, up from $2.1
million in the prior quarter and $1.6 million in the first quarter of
2015.
— Total underwriting and operating expenses in the first quarter were
$22.7 million, including share-based compensation expense of $1.4
million. This compares with total underwriting and operating expenses of
$21.7 million, including $2.3 million of share-based compensation, in
the prior quarter, and $18.4 million, including $2.0 million of share-
based compensation, in the same quarter a year ago.
— As of the end of the first quarter, the company had approved master
policies in place with 1,023 customers, up from 964 as of the end of the
prior quarter, and up from 777 as of the end of the first quarter of
2015. Customers delivering NIW in the quarter grew to a new high of 469,
which compares with 427 in the prior quarter and 291 in the same quarter
a year ago. On an ever-to-date basis, customers delivering NIW grew to
594.
— As of Mar. 31, 2016, the company had primary insurance-in-force of $18.6
billion, which compares with $14.8 billion at the prior quarter end and
$4.8 billion as of Mar. 31, 2015. Pool insurance-in-force as of the end
of the first quarter was $4.1 billion, which compares with $4.2 billion
at the prior quarter-end and $4.6 billion as of Mar. 31, 2015.
— At quarter-end, cash and investments were $630 million, including $84
million at the holding company, and book equity was $410 million, equal
to $6.94 per share. This book value excludes any benefit attributable to
the company’s deferred tax asset of approximately $66 million as of Dec.
31, 2015.
— At quarter-end, the company had total PMIERs available assets of $434
million and based on its current risk- in-force was required to maintain
PMIERs assets of $303 million.
Outlook

— The company currently expects to write in the range of $19- $20 billion
of new insurance in 2016.
— To support this growth, the company expects in 2016 to execute
reinsurance arrangements that would defer indefinitely the need for
additional equity capital.
— The company currently expects to achieve GAAP profitability in the
second half of 2016. This outlook includes the impact of expected NIW
growth, growth in volume-related expenses, and reinsurance.

Source – NMIH Press Release

 

 

 

Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.

 

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.

See feature articles below:

 

About Broad Street Alerts:

Big opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

 

Article for Titan Pharmaceuticals

 

SOUTH SAN FRANCISCO, CA — (Marketwired) — 04/15/16 — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today the presentation of data from the last Phase 3 study of Probuphine®, a six month subdermal buprenorphine implant for the long-term maintenance treatment of opioid addiction, at a poster session during the 47th Annual American Society of Addiction Medicine (ASAM) Annual Conference. The data indicates that participants who were clinically stable on sublingual buprenorphine at a dose of 8mg or less per day maintained stability when transferred to Probuphine, and that they were more likely to sustain abstinence from illicit opioids throughout the six months than participants who remained on sublingual buprenorphine. The Probuphine New Drug Application (NDA) is currently under review by the FDA with an action date of May 27, 2016.

“This was the first head-to-head comparison study of Probuphine and sublingual buprenorphine, demonstrating the efficacy of a long-acting six month buprenorphine implant,” said co-lead investigator and an author of the presentation Richard N. Rosenthal, M.D., Professor of Psychiatry and Medical Director of Addiction Psychiatry at the Icahn School of Medicine at Mount Sinai. “The study results show that participants in the implant group sustained clinical stability over the course of six months. The implant group was also more likely to remain free from illicit opioids at 85.7% compared to 71.9% of those maintained on sublingual buprenorphine. If approved, Probuphine could help expand access to medication to treat opioid use disorders, providing people with a new option.”

The poster titled, “A Randomized Trial of Probuphine Implants in Adults Stabilized on Sublingual Buprenorphine,” presented data from the double-blind, double-dummy study, which was designed to determine the efficacy and safety of Probuphine as a maintenance treatment for opioid addiction. The primary endpoint was a non-inferiority comparison of the Probuphine and the sublingual buprenorphine treatment arms. As previously reported, the study met its primary endpoint as well as all secondary endpoints, and the treatment was well tolerated by the study subjects. Further details are included in the poster presentation, which was co-authored by Michelle R. Lofwall, M.D., University of Kentucky College of Medicine, Center on Drug and Alcohol Research in Lexington, Kentucky; Sonnie Kim, Ph.D., Braeburn Pharmaceuticals; Katherine L. Beebe, Ph.D., Titan Pharmaceuticals; Michael Chen, Ph.D., TCM Groups, Inc.; and Frank J. Vocci, Ph.D., Friends Research Institute.

“We are very pleased to be presenting these important data for the first time at the ASAM meeting and will continue to work closely with our partner, Braeburn Pharmaceuticals, on a broad medical communications strategy for Probuphine, if approved by the FDA,” said Kate Beebe, Ph.D., Executive Vice President and Chief Development Officer of Titan Pharmaceuticals.

Probuphine was developed using Titan’s proprietary platform technology, ProNeura™, a non-biodegradable drug delivery implant designed to provide continuous, long- term steady state levels of medication in the blood. In January 2016, the FDA reviewed the Probuphine NDA at a meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC), and following a discussion of the data presented, the committee voted 12-5 in favor of approval of Probuphine. If approved by the FDA, Probuphine would be the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single procedure.

About the ProNeura Long-term Drug Delivery Platform
ProNeura is Titan’s proprietary, long-term drug delivery platform utilized in the development of products for the treatment of select chronic conditions that may benefit from the delivery of continuous, non-fluctuating levels of certain medications over an extended period of six months to a year. ProNeura consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subdermally, normally in the inner part of the upper arm, during a simple office procedure, and is removed in a similar manner at the end of treatment. The drug substance is released continuously through the process of dissolution, resulting in a stable, non-fluctuating blood level similar to that seen with intravenous administration. These long-term, linear-release characteristics are medically desirable to avoid the peak and trough swings from oral dosing that pose problems in the current treatments for many diseases, especially diseases of the central nervous system. Titan has issued patents as well as patent applications covering the use of the ProNeura long-term drug delivery platform for the formulation of specific products for the treatment of certain chronic diseases, such as opioid addiction, Parkinson’s disease, and others.

About Titan Pharmaceuticals
Titan Pharmaceuticals Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company’s lead product candidate is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan’s proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has granted U.S. and Canadian commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions, such as Parkinson’s disease, where maintaining consistent blood levels of a therapeutic agent may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.

 

Source TTNP Press Release

 

 

Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.

 

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.

See feature articles below:

About Broad Street Alerts:
Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Article for Ampio Pharmaceuticals

 

ENGLEWOOD, Colo., March 29, 2016 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that enrollment is now complete in the PIVOT trial of Ampion™ for the treatment of pain due to osteoarthritis-of-the-knee (OAK).

Michael Macaluso, Ampio’s CEO explained: “The PIVOT trial is a randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of an intra-articular injection of AMPION^™ in adults with pain due to osteoarthritis of the knee that was conducted in accordance with a Special Protocol Assessment (SPA) issued by the FDA. A Special Protocol Assessment (SPA) is a written agreement between the FDA and the sponsor company (Ampio Pharmaceuticals), which defines the clinical trial end-points required for approval and significantly reduces the risk of bringing a drug to market. This second pivotal trial is clinically identical to the previously successful Spring Study, which was confirmed by the agency as one of the two pivotal trials required for approval.  Our goal is to meet the clinical obligations for a novel biologic, a special designation that comes with 12 years of market exclusivity.

When we commenced the PIVOT Phase III Study in September 2015, we estimated the trial to require 484 patients. However the written guidance from the FDA required 464 patients, powered at 88%. The trial closed at 480 patients with approximately 60% of the patients already completing the 12-week period following dosing. Accordingly, we expect final results to be available mid-year 2016. A full description of the trial is outlined at:

https://clinicaltrials.gov/ct2/show/NCT02556710?term=ampion&rank=2%20%E2%80%9C.”

About Osteoarthritis
Osteoarthritis is the most common form of arthritis, affecting over 27 million people in the United States. It is a progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments, and bone. The incidence of developing osteoarthritis of the knee or hip over a lifetime is approximately 46% and 25%, respectively. Certain risk factors in conjunction with natural wear and tear lead to the breakdown of cartilage. Osteoarthritis is caused by inflammation of the soft tissue and bony structures of the joint, which worsens over time and leads to progressive thinning of articular cartilage. Other symptoms include narrowing of the joint space, synovial membrane thickening, osteophyte formation and increased density of subchondral bone.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements
Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to the Ampion™ PIVOT trial, as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. These forward-looking statements also include statements regarding the Special Protocol Assessment (SPA) as well as the classification of Ampion™ as a novel biologic with 12 years exclusivity. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Source – Ampio Press Release
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.

See feature articles below:

About Broad Street Alerts:
Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Article for CTIX

 

– See more at: http://cellceutix.com/cellceutix-completes-dosing-in-phase-2-trial-of-prurisol-for-chronic-psoriasis-top-line-data-anticipated-in-may/#sthash.mOTnr6WS.a85MFXSJ.dpuf

Source – CTIX Press Release
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.